IMMP Immutep Limited

2.88
+0.07  (+2%)
Previous Close 2.81
Open 2.73
Price To Book 6.13
Market Cap 98,259,157
Shares 34,117,763
Volume 453,953
Short Ratio
Av. Daily Volume 180,097
Stock charts supplied by TradingView

NewsSee all news

  1. WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321

    SHANGHAI, Feb. 23, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development

  2. Immutep Reports Positive TACTI-002 Data

    Encouraging Overall Response Rates (ORR) reported from stage 1 Parts A and C, with responses in 47% of 1st line non-small cell lung cancer (NSCLC) patients and already 33% of 2nd line head and neck squamous cell

  3. Immutep to Present TACTI-002 Interim Data at German Cancer Congress

    SYDNEY, Australia, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  4. Immutep Activities Report

    First progression-free survival ("PFS") data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020More mature data expected from TACTI-002 in February 2020Sufficiently funded to deliver

  5. Immutep Expands Part C of TACTI-002 Due to Positive Data

    Recruitment completed for stage 1 of Part C of TACTI-002 trial, for patients with second line Head and Neck Squamous Cell Carcinoma (HNSCC)Part C has been expanded to include an additional 19 HNSCC patients, creating

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b PFS data due March 2020.
Eftilagimod Alpha - Active Immunotherapy PAClitaxel (AIPAC)
Metastatic breast cancer (MBC)
Phase 1 final safety data due 2H 2020.
Eftilagimod alpha and Keytruda (TACTI-mel)
Melanoma
Phase 2 data released February 19, 2020 noted initial overall response rate of 47% for 1st line NSCLC ; 33% for 2nd line HNSCC patients.
Eftilagimod alpha and Keytruda - TACTI-002
Non-small cell lung cancer; Head and neck cancer
Phase 1 initial data released December 18, 2019. 1/6 partial responses. Further data due 2H 2020.
Eftilagimod alpha - INSIGHT-004
Solid tumors
Phase 2 trial to be completed August 2022.
GSK2831781
Ulcerative Colitis

Latest News

  1. WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321

    SHANGHAI, Feb. 23, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development

  2. Immutep Reports Positive TACTI-002 Data

    Encouraging Overall Response Rates (ORR) reported from stage 1 Parts A and C, with responses in 47% of 1st line non-small cell lung cancer (NSCLC) patients and already 33% of 2nd line head and neck squamous cell

  3. Immutep to Present TACTI-002 Interim Data at German Cancer Congress

    SYDNEY, Australia, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  4. Immutep Activities Report

    First progression-free survival ("PFS") data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020More mature data expected from TACTI-002 in February 2020Sufficiently funded to deliver

  5. Immutep Expands Part C of TACTI-002 Due to Positive Data

    Recruitment completed for stage 1 of Part C of TACTI-002 trial, for patients with second line Head and Neck Squamous Cell Carcinoma (HNSCC)Part C has been expanded to include an additional 19 HNSCC patients, creating

  6. INSIGHT-004 Clinical Trial Update

    Recruitment commenced for second cohort of 6 patients at higher efti dose combined with avelumabNo new safety signals in the first cohort, with 1 patient reporting a partial responseMore data expected to be reported in

  7. Immutep Announces European Patent Grant for LAG525 Antibody

    SYDNEY, Australia, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company") is pleased to announce the grant of patent no. 3116909 entitled "Antibody molecules to

  8. Immutep Presents Positive Interim Data From Phase II TACTI-002 Trial at SITC

    Part A comprises NSCLC patients with all levels of PD-L1 expression, being an all comer trialPreliminary Overall Response Rate (ORR) of 41% from stage 11 of Part A  ORR compares favourably to standard of care treatments

  9. Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma

    Key Trial Findings Favourable safety profile of eftilagimod alpha in combination with pembrolizumabDeep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in part A and B

  10. Immutep Receives A$2.5 Million R&D Tax Incentive from French Government

    SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  11. Immutep Announces Data Presentations at Upcoming Industry Conferences

    SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  12. Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data

    Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2Recruitment of cohort 2 of Part A of TACTI-002, additional 19

  13. Immutep to Receive £4M Milestone Payment From GSK

    SYDNEY, Australia, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  14. Immutep Announces Japanese Patent Grant for LAG525 Antibody

    SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company") is pleased to announce the grant of patent no. 6576962 entitled "Antibody molecules to

  15. Immutep Granted European Patent for Eftilagimod Alpha in Cancer

    SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and